Dung Thai

2.0k total citations
35 papers, 708 citations indexed

About

Dung Thai is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dung Thai has authored 35 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dung Thai's work include Gastric Cancer Management and Outcomes (8 papers), Peptidase Inhibition and Analysis (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Dung Thai is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Peptidase Inhibition and Analysis (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Dung Thai collaborates with scholars based in United States, United Kingdom and China. Dung Thai's co-authors include Jo Ellen Dyer, Christine Haller, Peyton Jacob, Hai Yan, Neal L. Benowitz, James M. Perel, Zev A. Wainberg, Henry Rapoport, Johanna C. Bendell and Manish A. Shah and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Dung Thai

33 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dung Thai United States	15	218	157	145	129	121	35	708
Rivka Hadar Israel	17	312 1.4×	84 0.5×	136 0.9×	139 1.1×	21 0.2×	37	841
Gilles‐Jacques Rivière Switzerland	18	351 1.6×	254 1.6×	99 0.7×	153 1.2×	31 0.3×	19	865
Jürgen Fingerle Switzerland	18	238 1.1×	58 0.4×	108 0.7×	33 0.3×	17 0.1×	26	724
Christel Menet Belgium	17	265 1.2×	189 1.2×	139 1.0×	254 2.0×	10 0.1×	27	1.3k
F. Sala Italy	13	223 1.0×	65 0.4×	67 0.5×	178 1.4×	16 0.1×	22	620
Vanessa Rausch Germany	22	717 3.3×	53 0.3×	140 1.0×	437 3.4×	39 0.3×	53	1.5k
Guowei Zhou China	15	226 1.0×	83 0.5×	72 0.5×	113 0.9×	6 0.0×	44	620
Paul DaSilva‐Jardine United States	12	270 1.2×	92 0.6×	64 0.4×	115 0.9×	13 0.1×	16	659
Christian Mang Germany	15	407 1.9×	52 0.3×	38 0.3×	137 1.1×	12 0.1×	25	1.1k
Péter Arányi Hungary	17	305 1.4×	64 0.4×	71 0.5×	48 0.4×	9 0.1×	76	753

Countries citing papers authored by Dung Thai

Since Specialization

Citations

This map shows the geographic impact of Dung Thai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dung Thai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dung Thai more than expected).

Fields of papers citing papers by Dung Thai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dung Thai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dung Thai. The network helps show where Dung Thai may publish in the future.

Co-authorship network of co-authors of Dung Thai

This figure shows the co-authorship network connecting the top 25 collaborators of Dung Thai. A scholar is included among the top collaborators of Dung Thai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dung Thai. Dung Thai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ball, Brian, Wenbin Xiao, Gautam Borthakur, et al.. (2025). Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML. Journal of Hematology & Oncology. 18(1). 73–73. 1 indexed citations

Odegard, Jared, Ahmed A. Othman, Kai-Wen Lin, et al.. (2024). Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(4). e008547–e008547. 8 indexed citations

Pettus, Jeremy, Schafer Boeder, Mark P. Christiansen, et al.. (2022). Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nature Medicine. 28(10). 2092–2099. 39 indexed citations

Ooki, Akira, Taroh Satoh, Kei Muro, et al.. (2022). A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. Scientific Reports. 12(1). 11007–11007. 6 indexed citations

Chourasia, Aparajita H., Paul Erdman, Ashwini Oke, et al.. (2022). BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1/3, for treatment of acute myeloid leukemia (AML) and solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 7025–7025. 13 indexed citations

Yamaguchi, Kensei, Kei Muro, Atsuo Takashima, et al.. (2022). Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. Journal for ImmunoTherapy of Cancer. 10(1). e003518–e003518. 9 indexed citations

Ball, Brian, Gautam Borthakur, Anthony S. Stein, et al.. (2022). Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51.. Journal of Clinical Oncology. 40(16_suppl). 7030–7030. 4 indexed citations

Bendell, Johanna C., Sunil Sharma, Manish R. Patel, et al.. (2020). Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. The Oncologist. 25(11). 954–962. 19 indexed citations

Gao, Chen, Shuxun Ren, Junyi Yu, et al.. (2019). Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. JACC Basic to Translational Science. 4(2). 161–172. 20 indexed citations

10.

Karwi, Qutuba G., Liyan Zhang, Cory S. Wagg, et al.. (2019). Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction. Cardiovascular Diabetology. 18(1). 1–1. 68 indexed citations

11.

Wei, Rui, Liangbiao Gu, Jin Yang, et al.. (2019). Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice. iScience. 16. 326–339. 32 indexed citations

12.

Metges, Jean‐Philippe, Emon Elboudwarej, David Cunningham, et al.. (2019). Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.. Journal of Clinical Oncology. 37(4_suppl). 148–148. 1 indexed citations

13.

Shah, Manish A., Jean‐Philippe Metges, David Cunningham, et al.. (2019). A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology. 37(4_suppl). 75–75. 6 indexed citations

14.

Bendell, Johanna C., Alexander Starodub, Manish A. Shah, et al.. (2015). Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 4030–4030. 8 indexed citations

15.

Patrick, Michael J., et al.. (2007). Enhanced aqueous solubility of long wavelength voltage-sensitive dyes by covalent attachment of polyethylene glycol. Organic & Biomolecular Chemistry. 5(20). 3347–3347. 12 indexed citations

16.

Thai, Dung, Jo Ellen Dyer, Peyton Jacob, & Christine Haller. (2006). Clinical Pharmacology of 1,4-Butanediol and Gamma-hydroxybutyrate After Oral 1,4-Butanediol Administration to Healthy Volunteers. Clinical Pharmacology & Therapeutics. 81(2). 178–184. 46 indexed citations

17.

Haller, Christine, Dung Thai, Peyton Jacob, & Jo Ellen Dyer. (2006). GHB Urine Concentrations After Single-Dose Administration in Humans. Journal of Analytical Toxicology. 30(6). 360–364. 43 indexed citations

18.

Thai, Dung, Jo Ellen Dyer, Neal L. Benowitz, & Christine Haller. (2006). Gamma-hydroxybutyrate and Ethanol Effects and Interactions in Humans. Journal of Clinical Psychopharmacology. 26(5). 524–529. 68 indexed citations

19.

Thai, Dung, et al.. (1999). Comparative Pharmacokinetics and Tissue Distribution of the d-Enantiomers of Para-Substituted Methylphenidate Analogs. Drug Metabolism and Disposition. 27(6). 645–650. 28 indexed citations

20.

Thai, Dung, et al.. (1998). Asymmetric Synthesis and Pharmacology of Methylphenidate and Its Para-Substituted Derivatives. Journal of Medicinal Chemistry. 41(4). 591–601. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact